News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

India Revokes Patent for Pfizer Inc. (PFE)'s Sutent


10/4/2012 7:51:58 AM

India has revoked Pfizer Inc.’s local patent for its cancer drug Sutent after hearing a pre-grant opposition filed by generic drug maker Cipla Ltd. Cipla and a few other local drug makers, including Natco Pharma Ltd, had opposed the Indian patent for Sutent, a liver and kidney cancer drug sold by Pfizer worldwide. The drug, known as Sunitinib in generic terms, was developed by US drug makers Sugen Inc. and Pharmacia and Upjohn Co. and licensed to Pfizer for marketing it globally. The drug was granted a patent in India in 2007. Cipla opposed the patent grant the following year.

Read at Live Mint

comments powered by Disqus
Live Mint
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES